A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05981703

Public ClinicalTrials.gov record NCT05981703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 14, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

Study identification

NCT ID: NCT05981703
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: BeOne Medicines; Industry
Enrollment: 337 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 20, 2023
Primary completion: Feb 27, 2029
Completion: Feb 27, 2029
Last update posted: Aug 31, 2026

2023 – 2029

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010-3012	Recruiting
University of Southern California Norris Comprehensive	Los Angeles	California	90033	Recruiting
Yale University Yale Cancer Center	New Haven	Connecticut	06520-8028	Recruiting
Sylvester Cancer Center, University of Miami	Miami	Florida	33136	Recruiting
University of Michigan Health System	Ann Arbor	Michigan	48109-5316	Recruiting
John Theurer Cancer Center Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
Icahn School of Medicine At Mount Sinai	New York	New York	10029-6504	Recruiting
Providence Portland Medical Center	Portland	Oregon	97213-2933	Recruiting
The University of Texas Md Anderson Cancer Center	Houston	Texas	77030-4009	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05981703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 31, 2026 · Synced Sep 14, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05981703 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →